ColoPrint is an 18-gene expression signature designed to predict disease relapse in patients with early-stage colorectal cancer (CRC). We discuss the potential impact of ColoPrint on clinical practice, and its contribution to our knowledge of CRC molecular heterogeneity.
Related Articles
Impact Factor
Failure of bevacizumab in early-stage colon cancer
News
EuropaColon expands into Digestive Cancers Europe
Senza categoria